Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feladilimab plus Ipilimumab in NSCLC
NCT06790303Phase 2Terminated
- Sponsor
- GSK
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of feladilimab in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Mar 2021; status: terminated.
02
Drugs
feladilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06790303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790303.